A detailed history of Wells Fargo & Company transactions in Immatics N.V. stock. As of the latest transaction made, Wells Fargo & Company holds 14 shares of IMTX stock, worth $129. This represents 0.0% of its overall portfolio holdings.

Number of Shares
14
Holding current value
$129
% of portfolio
0.0%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$9.78 - $13.49 $136 - $188
14 New
14 $0
Q4 2022

Feb 13, 2023

BUY
$8.05 - $11.58 $6,021 - $8,661
748 New
748 $6,000

Others Institutions Holding IMTX

About Immatics N.V.


  • Ticker IMTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,227,000
  • Market Cap $705M
  • Description
  • Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive c...
More about IMTX
Track This Portfolio

Track Wells Fargo & Company Portfolio

Follow Wells Fargo & Company and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.